** Sage Therapeutics' shares fall 5.5% to $6.87 in morning trade
** Co says it will lay off more than 165 employees, including more than half of its R&D team, as part of reorganization plan
** To prioritize launch of postpartum depression pill Zurzuvae, which has been jointly developed with Biogen , and early-stage experimental drugs
** Last week, co said it would stop developing its experimental drug dalzanemdor, for Alzheimer's disease after it failed to meet main goal in late-stage trial
** Avg recommendation of 19 brokerages is a "hold;" median PT is $10 - LSEG
** As of last close, stock had slumped 66.5% YTD vs 11% increase in Nasdaq Biotechnology index
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。